First-line pertuzumab (P), trastuzumab (H), and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC): Interim safety results (N=704) from PERUSE.
Thomas Denis Bachelot
Consultant or Advisory Role - Roche
Research Funding - Roche
Eva Ciruelos
No relevant relationships to disclose
Tamar Peretz-Yablonski
Consultant or Advisory Role - Roche (U)
Research Funding - Roche
Fabio Puglisi
Consultant or Advisory Role - Roche
Honoraria - Roche
Andreas Schneeweiss
Consultant or Advisory Role - Celgene; Medac; Roche
Honoraria - AstraZeneca; Celgene; Eisai; GlaxoSmithKline; Novartis; Roche
Research Funding - Celgene; Roche
Mario Campone
Consultant or Advisory Role - Novartis; SERVIER
Honoraria - Novartis; SERVIER
Bruno P. Coudert
Consultant or Advisory Role - Amgen; Genomic Health; Lilly; Pfizer; Roche
Bella Kaufman
Consultant or Advisory Role - Roche
Honoraria - Roche
Andrew M. Wardley
Consultant or Advisory Role - Roche
Honoraria - Roche
Other Remuneration - Roche
Lydie Bastiere-Truchot
Employment or Leadership Position - Roche
Stock Ownership - Roche
Ulrich Freudensprung
Employment or Leadership Position - Roche
Eleonora Restuccia
Employment or Leadership Position - Roche
David Miles
Honoraria - Roche